Impavido Designated Orphan Drug for Amebic Meningoencephalitis

Impavido is already approved for the treatment of visceral, cutaneous, and mucosal leishmaniasis
Impavido is already approved for the treatment of visceral, cutaneous, and mucosal leishmaniasis

Profounda announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for Impavido (miltefosine) to treat primary amebic meningoencephalitis (PAM), also known as the "Brain Eating Amoeba". 

Earlier this year, Impavido was used to successfully treat a patient in the Orlando area with a Naegleria fowleri infection. Impavido, an alkylphosphocholine compound, works by acting on key enzymes involved in phospholipid and sterol biosynthesis. As a result of excellent passage though the blood-brain barrier, miltefosine is able to achieve high concentrations of the active drug in the brain tissue.  

Related Articles

Impavido is already approved for the treatment of visceral, cutaneous, and mucosal leishmaniasis due to susceptible Leishmania species. It showed in vitro activity against the promastigote and amastigote stages of the Leishmania stages.

Impavido is available as 50mg hard gel capsules in 2x14 blister cards.

For more information call (866) 588-5405 or visit Impavido.com.